Equity Overview
Price & Market Data
Price: $12.82
Daily Change: -$0.18 / 1.40%
Daily Range: $12.59 - $13.00
Market Cap: $20,553,780
Daily Volume: 2,677
Performance Metrics
1 Week: -3.75%
1 Month: -7.44%
3 Months: -7.10%
6 Months: 8.64%
1 Year: -8.75%
YTD: -4.97%
Company Details
Employees: 1
Sector: Health services
Industry: Medical/Nursing services
Country:
Details
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.